Benzamide, N-(4-ethoxyphenyl)-4-(2H-tetrazol-5-yl)-
Benzamide, N-(4-ethoxyphenyl)-4-(2H-tetrazol-5-yl)- Basic information
- Product Name:
- Benzamide, N-(4-ethoxyphenyl)-4-(2H-tetrazol-5-yl)-
- Synonyms:
-
- Benzamide, N-(4-ethoxyphenyl)-4-(2H-tetrazol-5-yl)-
- Xanthine oxidoreductase-IN-4
- N-(4-Ethoxyphenyl)-4-(1H-tetrazol-5-yl)benzamide
- CAS:
- 1026587-58-5
- MF:
- C16H15N5O2
- MW:
- 309.32
- Mol File:
- 1026587-58-5.mol
More
Less
Benzamide, N-(4-ethoxyphenyl)-4-(2H-tetrazol-5-yl)- Chemical Properties
- Density
- 1.332±0.06 g/cm3(Predicted)
- pka
- 3.81±0.10(Predicted)
More
Less
Benzamide, N-(4-ethoxyphenyl)-4-(2H-tetrazol-5-yl)- Usage And Synthesis
Uses
Xanthine oxidoreductase-IN-4 is an orally active xanthine oxidoreductase (XOR) inhibitor. Xanthine oxidoreductase-IN-4 has inhibitory activity against XOR with an IC50 value of 29.3 nM. Xanthine oxidoreductase-IN-4 can be used for the research of hyperuricemia[1].
in vivo
Xanthine oxidoreductase-IN-4 (Compound IIIc) (oral; 5 mg/kg) shows a significant hypouricemia effect in a potassium oxazinate/hypoxanthine-induced model of acute hyperuricemia[1].
| Animal Model: | Mice acute hyperuricemia model[1] |
| Dosage: | 5 mg/kg |
| Administration: | Oral |
| Result: | Reduced serum levels of uric acid significantly from 4 h after administration. |
References
[1] Wen Peng, et al. Design, synthesis, and evaluation of tricyclic compounds containing phenyl-tetrazole as XOR inhibitors. Eur J Med Chem. 2022 Nov 28;246:114947. DOI:10.1016/j.ejmech.2022.114947
Benzamide, N-(4-ethoxyphenyl)-4-(2H-tetrazol-5-yl)-Supplier
Shanghai YuanYe Biotechnology Co., Ltd.
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
Tianjin Kailiqi Biotechnology Co., Ltd.
- Tel
- 15076683720
- klq@cw-bio.com
Shanghai Chaolan Chemical Technology Center
- Tel
- 021-QQ：65489617 15618227136
- Sales@ATKchemical.com
TargetMol Chemicals Inc.
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
Bide Pharmatech Ltd.
- Tel
- 400-1647117 13681763483
- product02@bidepharm.com